Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer.

Zev A WainbergHoward S HochsterEdward J KimBen GeorgeAparna KaylanE Gabriela ChioreanDavid M WaterhouseMartin GuiterrezAparna ParikhRishi JainDaniel Ricardo CarrizosaHatem H SolimanThomas LilaDavid J ReissDaniel W PierceRafia BhoreSibabrata BanerjeeLarry LyonsChrystal U LouisTeng Jin OngPeter J O'Dwyer

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The safety profile of nivolumab plus nab-paclitaxel and gemcitabine at standard doses in advanced pancreatic cancer was manageable, with no unexpected safety signals. Overall, the clinical results of this study do not support further investigation.

Keyphrases

clinical trial
advanced non small cell lung cancer
locally advanced
radiation therapy
rectal cancer
tyrosine kinase
phase ii
phase iii